Merck KGaA has announced plans to acquire SpringWorks, a biotech company specializing in treatments for rare cancers, in a deal valued at $3.9 billion. This acquisition aims to bolster Merck KGaA’s portfolio in oncology, focusing on innovative therapies for underserved patient populations. The transaction underscores Merck KGaA’s commitment to expanding its presence in the biopharmaceutical sector and advancing treatments for rare diseases. Financial details and closing conditions are expected to be finalized in the coming months.
— new from Endpoints News
